Opthea
Opthea is committed to improving vision in patients suffering with retinal eye diseases.
Opthea is committed to improving vision in patients suffering with retinal eye diseases.
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn. Enquiries can be directed to: [email protected]
There is no investment information
No recent news or press coverage available for Opthea.
We care about your data, and we'd love to use cookies make your experience better.
